All
FDA Approves Polivy Regimen for DLBCL
April 19th 2023The Food and Drug Administration approved Polivy plus Rituxan, cyclophosphamide, doxorubicin and prednisone for patients with previously untreated diffuse large B-cell lymphoma — marking the first new regimen in nearly two decades for this patient population.
FDA Accepts Application Seeking Approval of Keytruda-Chemo Combo for Stomach Cancer Subtypes
April 13th 2023If approved by the FDA, Keytruda plus chemotherapy could provide a frontline therapy for patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.